Tempus AI, Inc. (TEM) Form 10-Q — Nov 2, 2026
Tempus AI reported Q3 2026 revenue of $411.5 million, up roughly 23% year-over-year, with Diagnostics at $303.5 million and Data and applications at $108.1 million. Net loss narrowed dramatically to $14.9 million ($0.08 per share) from $80.0 million a year ago, aided by $47.1 million of other income. The balance sheet shows $590.5 million in cash against $1.17 billion of convertible senior notes (net), including $460 million of 0.00% notes due 2032 issued in May 2026 and $750 million of 0.75% notes due 2030. Management stated existing cash and marketable securities are sufficient to fund the operating plan through at least one year.
Key figures
- Revenue
- 411537000
- Total Debt
- 1174877000
- Total Assets
- 2451598000
- Cash Position
- 590479000
- Shares Outstanding
- 177357848
- Goodwill
- 488142000
- Q3 2025 revenue
- 334206000
- Notes 2030 principal
- 750000000
- Notes 2032 principal
- 460000000
- Atm capacity remaining
- 300000000
- Diagnostics revenue q3
- 303470000
- Nine month revenue 2025
- 904578000
- Nine month revenue 2026
- 1142139000
- Personalis price per share
- 16.25
- Personalis termination fee
- 76800000
- Convertible senior notes net
- 1174877000
- Center health acquisition value
- 18800000
- Data and applications revenue q3
- 108067000
- Remaining performance obligations
- 514000000
- Stock based compensation nine months
- 154901000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.